-

Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that Chief Executive Officer, Shawn Singh, will participate in the following upcoming investor conferences in New York. Management will be available for one-on-one meetings during these conferences.

Morgan Stanley 20th Annual Global Healthcare Conference

Format: Fireside Chat
Date and Time: Tuesday, September 13th at 9:10 a.m. Eastern Time
Location: New York, New York
Webcast will be accessible through the Events page in the Investors section of the Company’s website at www.Vistagen.com.

Baird 2022 Global Healthcare Conference

Format: Fireside Chat
Date and Time: Wednesday, September 14th at 2:35 p.m. Eastern Time
Location: New York, New York

About Vistagen

Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.

Contacts

Investors:
Mark Flather
Vice President, Investor Relations
(650) 577-3617
mflather@vistagen.com

Media:
Nate Hitchings
SKDK
nhitchings@skdknick.com

Vistagen Therapeutics, Inc.

NASDAQ:VTGN

Release Summary
Vistagen to Participate in Fireside Chats at Morgan Stanley and Baird Healthcare Conferences
Release Versions
$Cashtags

Contacts

Investors:
Mark Flather
Vice President, Investor Relations
(650) 577-3617
mflather@vistagen.com

Media:
Nate Hitchings
SKDK
nhitchings@skdknick.com

Social Media Profiles
More News From Vistagen Therapeutics, Inc.

Vistagen Appoints Nick Tressler as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operationa...

Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented exploratory data at The Menopause Society 2025 Annual Meeting in Orlando, Florida. These findings demonstrate PH80’s potential as a rapidly-acting pherine product candidate for treating vasomotor symptoms (hot flashes) du...

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. “As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain...
Back to Newsroom